637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT)

Prospera ABNL MARRO 002 A randomized phase 2 study of pacritinib vs hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia CMML

Short term outcomes of rituximab versus thrombopoietin receptor agonists in Myelodysplastic Syndromes A 90 day propensity matched analysis using real world data

Molecular subclusters across the continuum of myelodysplastic neoplasms and acute myeloid leukaemia define distinct clinical entities

Temporal trends in overall survival among patients with high risk MDS Insights from the spanish MDS registry RESMD

Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia

From chaos to clarity decoding the inflammatory profiles in lower risk MDS

The prognostic significance or lack of achieving marrow complete remission mCR with hypomethylating agent based therapy in patients with myelodysplastic syndrome

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Cardiovascular disease in myelodysplastic syndromes and related disorders Frequency risk factors and outcomes

Comparative evaluation of ipss m and cpss mol in CMML Impact of molecular markers on prognosis

17p loss in TP53 non mutated myeloid neoplasms confers survival comparable to TP53 mutated disease

RUNX1 mutations define a high risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Elevated serum erythropoietin level is associated with unique clinical and genomic features response to treatment and outcomes in lower risk myelodysplastic syndromes

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients Interim analysis after four years of study commencement

TCL1A polymorphism predicts AML progression in myeloid neoplasms

Outcomes of hypomethylating agent HMA based therapy in patients with myelodysplastic syndrome with fibrosis

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes neoplasms MDS clinical trials An icMDS systematic review of published manuscripts

IDH mutant MDS Proposal for disease subset recognition based on molecular and clinical features and the availability of targeted therapies

Non infectious fever predicts poor survival in azacitidine treated high risk but not low risk myelodysplastic syndromes a multicenter real world cohort study KOTOSG

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification The progevo machine learning approach

Evaluation of levofloxacine as antibiotic prophylaxis in MDS and AML patients treated with azacitidine Results from the randomized open label phase III azabac study

Differential trends in survival after allogeneic transplantation for MDS and MDS MPN in a real world experience

Clonal evolution and risk assessment in myelodysplastic syndromes MDS A prospective Study of dynamic IPSS m validation and evolutionary trajectory modeling by the italian MDS foundation FISIM